Multiple sclerosis and COVID-19

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020 Sep;164(3):217-225. doi: 10.5507/bp.2020.033. Epub 2020 Jul 17.

Abstract

This paper reviews currently available data on the novel coronavirus and clinical features of COVID-19, followed by a detailed section on possible modifications of immunomodulatory therapy in multiple sclerosis patients with COVID-19, based on what we know so far. There are discussed: (i) The COVID-19 disease (Epidemiological background SARS-CoV-1 coronavirus; Autoimmune response to COVID-19; Asymptomatic course; SARS-CoV-2 test; COVID-19 symptoms), (ii) Treatment of COVID-19 (Experimental plasma treatment; Antiviral therapy; Antimalarial treatment scheme; Biological treatment; Corticosteroid treatment; Symptomatic treatment; Vaccine preparation) and (iii) Multiple sclerosis and SARS-CoV-2 infection (Epidemiological recommendation).

Keywords: COVID-19; coronavirus; immunomodulatory therapy; multiple sclerosis.

Publication types

  • Review

MeSH terms

  • Asymptomatic Diseases / epidemiology
  • Autoimmunity
  • Betacoronavirus / physiology
  • COVID-19
  • Coronavirus Infections* / epidemiology
  • Coronavirus Infections* / immunology
  • Coronavirus Infections* / therapy
  • Coronavirus Infections* / virology
  • Humans
  • Immunologic Factors / pharmacology*
  • Immunomodulation / immunology*
  • Multiple Sclerosis* / epidemiology
  • Multiple Sclerosis* / immunology
  • Multiple Sclerosis* / therapy
  • Pandemics*
  • Pneumonia, Viral* / epidemiology
  • Pneumonia, Viral* / immunology
  • Pneumonia, Viral* / therapy
  • Pneumonia, Viral* / virology
  • SARS-CoV-2

Substances

  • Immunologic Factors